Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

University of Alberta

$30,000.00

Nanoprecipitation for controlled formation of rasagaline mesylate (RM) microparticle agents

FY 2022-23

Summary
Parkinson's disease is a neurodegeneration disorder, affecting 1 in every 500 people in Canada. Rasagiline mesylate (RM) is a drug for treatment of Parkinson's disease. As a hydrophilic compound, RM has a short elimination half-life. Currently the clinical applications of RM for Parkinson's disease treatment are limited by its low bioavailability and the requirement of daily administrations. The quick and 'burst' release profiles of RM make it challenging for drug delivery systems. Through the partnership with Hermay Labs Corporation, the overall goal of the project is to develop a technology for producing RM microparticle agents used in control release systems. The project will employ a nanoprecipitation-based approach for producing RM microparticle agents by using an antisolvent. The physicochemical characteristics (size distribution, loading and encapsulation efficiency) of the agents will be controlled by both mixture composition and mixing dynamics of the antisolvent. The solubility diagrams of multiple components will be constructed to guide the selection of composition ratios. A novel 2D mixing device will be used to determine the composition for desirable properties of the particles. The formation of RM particle agents will be induced in a wide range of mixing rate of the RM solution and the antisolvent with presence of carrier materials to tune the release profile of the RM agents. The potential outcomes of the project will be (1) effective protocols for producing RM microparticle agents by nanoprecipitation; (2) correlations between mixing conditions and the characteristics of RM microparticles; (3) improved understanding of nanoprecipitation for hydrophilic compound in general for clinic medications; (4) Patents, presentations in conferences, and publications in peer-viewed journals. Four HQPs will be trained on this 2-year project. The research activities supported by NSERC is crucial for success and long-term impact of the project.
Program
Alliance Grants
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
580548-2022
Name nom
Zhang, Xuehua XH
Department département
Chemical and Materials Engineering
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1800
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Chemical engineering
Research subject fr
Génie chimique
Installment
inst:1
Partie
1
Nb partie
1
Application title
Nanoprecipitation for controlled formation of rasagaline mesylate (RM) microparticle agents
Application summary
Parkinson's disease is a neurodegeneration disorder, affecting 1 in every 500 people in Canada. Rasagiline mesylate (RM) is a drug for treatment of Parkinson's disease. As a hydrophilic compound, RM has a short elimination half-life. Currently the clinical applications of RM for Parkinson's disease treatment are limited by its low bioavailability and the requirement of daily administrations. The quick and 'burst' release profiles of RM make it challenging for drug delivery systems. Through the partnership with Hermay Labs Corporation, the overall goal of the project is to develop a technology for producing RM microparticle agents used in control release systems. The project will employ a nanoprecipitation-based approach for producing RM microparticle agents by using an antisolvent. The physicochemical characteristics (size distribution, loading and encapsulation efficiency) of the agents will be controlled by both mixture composition and mixing dynamics of the antisolvent. The solubility diagrams of multiple components will be constructed to guide the selection of composition ratios. A novel 2D mixing device will be used to determine the composition for desirable properties of the particles. The formation of RM particle agents will be induced in a wide range of mixing rate of the RM solution and the antisolvent with presence of carrier materials to tune the release profile of the RM agents. The potential outcomes of the project will be (1) effective protocols for producing RM microparticle agents by nanoprecipitation; (2) correlations between mixing conditions and the characteristics of RM microparticles; (3) improved understanding of nanoprecipitation for hydrophilic compound in general for clinic medications; (4) Patents, presentations in conferences, and publications in peer-viewed journals. Four HQPs will be trained on this 2-year project. The research activities supported by NSERC is crucial for success and long-term impact of the project.